pI: 7.9596 |
Length (AA): 53 |
MW (Da): 6196 |
Paralog Number:
2
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There is 1 model calculated for this protein. More info on
this model, including the
model itself is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
1 | 42 | 1w9k (A) | 421 | 465 | 43.00 | 0.32 | 0.13 | 0.943853 | 2.03 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Ortholog group members (OG5_128499)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT2G01690 | VAC 14-like protein |
Babesia bovis | BBOV_II007720 | conserved hypothetical protein |
Brugia malayi | Bm1_36015 | SD04925p |
Candida albicans | CaO19.6411 | similar to S. cerevisiae Vac14p, activator of lipid kinase Fab1p |
Candida albicans | CaO19.13769 | similar to S. cerevisiae Vac14p, activator of lipid kinase Fab1p |
Caenorhabditis elegans | CELE_K04G2.6 | Protein VACL-14 |
Dictyostelium discoideum | DDB_G0289233 | hypothetical protein |
Drosophila melanogaster | Dmel_CG5608 | CG5608 gene product from transcript CG5608-RA |
Echinococcus granulosus | EgrG_000652600 | protein VAC14 |
Echinococcus multilocularis | EmuJ_000652600 | protein VAC14 |
Homo sapiens | ENSG00000103043 | Vac14 homolog (S. cerevisiae) |
Leishmania braziliensis | LbrM.14.1640 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_141550.1 | Vacuolar 14 Fab1-binding region/Vacuolar protein 14 C-terminal Fig4p binding, putative |
Leishmania infantum | LinJ.14.1550 | hypothetical protein, conserved |
Leishmania major | LmjF.14.1450 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.14.1450 | hypothetical protein, conserved |
Loa Loa (eye worm) | LOAG_13991 | hypothetical protein |
Loa Loa (eye worm) | LOAG_05770 | hypothetical protein |
Loa Loa (eye worm) | LOAG_06773 | hypothetical protein |
Mus musculus | ENSMUSG00000010936 | Vac14 homolog (S. cerevisiae) |
Neospora caninum | NCLIV_018650 | hypothetical protein |
Oryza sativa | 4332109 | Os03g0223700 |
Plasmodium berghei | PBANKA_1440600 | VAC14 domain-containing protein, putative |
Plasmodium falciparum | PF3D7_1225700 | VAC14 domain-containing protein, putative |
Plasmodium knowlesi | PKNH_1445100 | VAC14 domain-containing protein, putative |
Plasmodium vivax | PVX_123915 | hypothetical protein, conserved |
Plasmodium yoelii | PY05852 | hypothetical protein |
Saccharomyces cerevisiae | YLR386W | Vac14p |
Schistosoma japonicum | Sjp_0111050 | hypothetical protein |
Schistosoma japonicum | Sjp_0131330 | Protein VAC14 homolog, putative |
Schistosoma mansoni | Smp_180010 | hypothetical protein |
Schistosoma mansoni | Smp_172820 | hypothetical protein |
Schmidtea mediterranea | mk4.011285.00 | |
Schmidtea mediterranea | mk4.000870.05 | Protein VAC14 homolog |
Trypanosoma brucei gambiense | Tbg972.7.3880 | hypothetical protein, conserved |
Trypanosoma brucei | Tb927.7.3530 | Vacuolar protein 14 C-terminal Fig4p binding, putative |
Trypanosoma congolense | TcIL3000_7_2750 | hypothetical protein, conserved |
Trypanosoma cruzi | TcCLB.506443.30 | Vacuolar protein 14 C-terminal Fig4p binding, putative |
Toxoplasma gondii | TGME49_244040 | HEAT repeat-containing protein |
Theileria parva | TP02_0688 | hypothetical protein |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.7.3530 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb927.7.3530 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.7.3530 | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb927.7.3530 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
PBANKA_1440600 | Plasmodium berghei | Essential | plasmo |
TGME49_244040 | Toxoplasma gondii | Probably essential | sidik |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Mus musculus | Vac14 homolog (S. cerevisiae) | Compounds | References |